首页> 美国卫生研究院文献>Annals of Oncology >Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
【2h】

Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

机译:高热性中性粒细胞减少症患者(不包括同种异体SCT)的肺浸润的诊断和抗菌治疗:德国血液病和肿瘤医学会传染病工作组(AGIHO)的最新指南

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Up to 25% of patients with profound neutropenia lasting for >10 days develop lung infiltrates, which frequently do not respond to broad-spectrum antibacterial therapy. While a causative pathogen remains undetected in the majority of cases, Aspergillus spp., Pneumocystis jirovecii, multi-resistant Gram-negative pathogens, mycobacteria or respiratory viruses may be involved. In at-risk patients who have received trimethoprim–sulfamethoxazole (TMP/SMX) prophylaxis, filamentous fungal pathogens appear to be predominant, yet commonly not proven at the time of treatment initiation. Pathogens isolated from blood cultures, bronchoalveolar lavage (BAL) or respiratory secretions are not always relevant for the etiology of pulmonary infiltrates and should therefore be interpreted critically. Laboratory tests for detecting Aspergillus galactomannan, β-d-glucan or DNA from blood, BAL or tissue samples may facilitate the diagnosis; however, most polymerase chain reaction assays are not yet standardized and validated. Apart from infectious agents, pulmonary side-effects from cytotoxic drugs, radiotherapy or pulmonary involvement by the underlying malignancy should be included into differential diagnosis and eventually be clarified by invasive diagnostic procedures. Pre-emptive treatment with mold-active systemic antifungal agents improves clinical outcome, while other microorganisms are preferably treated only when microbiologically documented. High-dose TMP/SMX is first choice for treatment of Pneumocystis pneumonia, while cytomegalovirus pneumonia is treated primarily with ganciclovir or foscarnet in most patients. In a considerable number of patients, clinical outcome may be favorable despite respiratory failure, so that intensive care should be unrestrictedly provided in patients whose prognosis is not desperate due to other reasons.
机译:持续时间超过10天的严重中性粒细胞减少症患者中,多达25%会出现肺浸润,这通常对广谱抗菌疗法无反应。尽管在大多数情况下仍未发现致病性病原体,但可能涉及曲霉属,吉氏肺孢菌,多重耐药革兰氏阴性病原体,分枝杆菌或呼吸道病毒。在接受甲氧苄氨嘧啶-磺胺甲基异恶唑(TMP / SMX)预防的高危患者中,丝状真菌病原体似乎占主导地位,但在治疗开始时通常尚未得到证实。从血液培养,支气管肺泡灌洗(BAL)或呼吸道分泌物中分离出的病原体与肺部浸润的病因并不总是相关的,因此应进行严格的解释。从血液,BAL或组织样本中检测半乳曲霉半乳甘露聚糖,β-d-葡聚糖或DNA的实验室测试可能有助于诊断;但是,大多数聚合酶链反应测定尚未标准化和验证。除感染因素外,细胞毒性药物的肺部副作用,放疗或潜在恶性肿瘤对肺部的影响也应包括在鉴别诊断中,并最终通过侵入性诊断程序加以阐明。用霉菌活性的系统性抗真菌药进行抢先治疗可改善临床效果,而其他微生物最好仅在有微生物记录时才进行治疗。大剂量TMP / SMX是治疗肺孢子虫肺炎的首选,而在大多数患者中主要使用更昔洛韦或膦甲酸治疗巨细胞病毒性肺炎。在许多患者中,尽管有呼吸衰竭,临床结果仍可能是有利的,因此,对于因其他原因而预后不佳的患者,应无限制地提供重症监护。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号